Drug Trial Radar · NCT06300203
Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis
Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Mar 18, 2024
Primary completion
Jun 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Beijing Tongren HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.
Conditions
- Seasonal Allergic Rhinitis
Interventions
Interleukin-4 receptor respondersBiological
Interleukin-4 receptor was injected subcutaneously.
PlaceboOther
Placebo was injected subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average change from baseline in daily retrospective total nasal symptom score (rTNSS) at week 2.Time frame: up to Week 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.